Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Business Wire•23/10/2026•16:37 ET
0
Key Highlights
- ➤Summit and Lunit sign research agreement for AI-powered tumor microenvironment analysis
- ➤Lunit SCOPE IO will analyze H&E whole-slide images without additional stains or assays
- ➤Research may support biomarker discovery, patient selection, and ivonescimab development
- ➤No clinical outcome data are being announced in the release
- ➤Ivonescimab has five Phase III studies with positive data to date
Expert Statements
Allen Yang, Chief Research and Development Strategy Officer of Summit
“Understanding the tumor microenvironment is increasingly important as immuno-oncology moves beyond single-axis checkpoint inhibition toward more complex mechanisms and combinations”
Allen Yang, Chief Research and Development Strategy Officer of Summit
“We are pleased to work with Lunit to explore how AI-powered pathology can help generate deeper, more scalable insights from routine tissue samples and inform the continued development of ivonescimab.”
Brandon Suh, CEO of Lunit
“Summit is at the forefront of next-generation immuno-oncology development, and we are excited to support its efforts with Lunit SCOPE IO”
Brandon Suh, CEO of Lunit
“By extracting quantitative, spatially resolved immune and tumor microenvironment features from standard H&E slides, we believe SCOPE IO can help biopharma partners better understand which patients may benefit from immuno-oncology therapies and why.”
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology
Get started
Create a free account to read the full story.